SecondWave Systems, a clinical-stage medical device company pioneering ultrasound-based therapies for inflammatory diseases, has announced the addition of Sectoral Asset Management to its Series A investment syndicate. The expanded financing will accelerate development and clinical progress of the company’s novel noninvasive therapeutic technology, the SecondWave MINI, a wearable ultrasound device designed to treat chronic and acute inflammatory disorders.
The new funding round strengthens SecondWave’s investor base, which already includes Treo Ventures, Scientific Health Development, the University of Minnesota, and a significant healthcare strategic investor. Sectoral Asset Management, known for its deep expertise in healthcare and medical technologies, joins the group to support SecondWave’s mission of providing innovative, non-pharmacological therapies to patients living with inflammatory diseases.
The SecondWave MINI is a first-of-its-kind, noninvasive wearable device that uses targeted ultrasound stimulation to activate the body’s anti-inflammatory pathways, specifically by stimulating the spleen. This proprietary technology represents a potential paradigm shift in the treatment of chronic inflammatory disorders such as rheumatoid arthritis and other autoimmune conditions.
The company’s approach aims to deliver an effective alternative to existing drug-based therapies, offering patients a safer, more convenient, and personalized treatment option.
SecondWave Systems, based in St. Paul, Minnesota, is currently conducting clinical studies to evaluate the therapeutic benefits of its ultrasound stimulation platform. The expanded Series A financing will enable the company to validate its platform’s efficacy further, support regulatory initiatives, and prepare for future commercialization.
The involvement of Sectoral Asset Management adds substantial experience in scaling medical device innovations from development through commercialization. The partnership marks an essential step in SecondWave’s journey to bring its noninvasive treatment technology to market and advance a new class of ultrasound-based therapies for inflammatory disease.
KEY QUOTES:
“The team at Sectoral has a wealth of experience and will bolster our ability to deliver life-altering therapy for patients who suffer from inflammatory disease.”
Anuj Bhardwaj, Chief Executive Officer, SecondWave Systems
“A large portion of patients with chronic inflammatory disease are looking for better therapies, and SecondWave’s ultrasound stimulation platform has the potential to become the solution of choice. Their elegant non-invasive approach may redefine how these patients are treated.”
Marc-André Marcotte, Partner and Head of Venture Capital, Sectoral Asset Management
